All News
A new mechanism of action in SARD-ILD
Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases.
Read Article
EULAR 2025 – Day 4 Report
Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. My favorite presentations included the following.
Read Article
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia
The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence and digital health technologies. At #EULAR2025, the Bechterew-App Trial (LB0002) presented important new data on Axia, a novel AI-powered digital therapeutic developed for axSpA.
Read Article
Seronegative Arthritis Breakthroughs
Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel https://t.co/7nmOWw11lb
Dr. John Cush RheumNow ( View Tweet)
Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD
Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 https://t.co/jPAai9FLkb
Dr. John Cush RheumNow ( View Tweet)
Sonelokimab in PsA
Dr. Adela Castro reports on OP0096, 'Impact of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody, on multidomain clinical outcomes in active psoriatic arthritis: results from the randomized, double-blind, placebo-controlled Phase 2 ARGO trial,' https://t.co/KmV6Rx4uFT
Dr. John Cush RheumNow ( View Tweet)
Health inequities in rheumatology: A central theme
This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases (RMDs). Across multiple sessions and studies, delegates are presenting compelling https://t.co/nmdyJYQV0B
Dr. John Cush RheumNow ( View Tweet)
Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis
In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/YDuUg44ebu
Dr. John Cush RheumNow ( View Tweet)
Transcranial Stimulation is Effective in Fibromyalgia
A randomized, controlled clinical trial in fibromyalgia (FM) has shown the efficacy of transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain. https://t.co/kJk1R8ubqk
Dr. John Cush RheumNow ( View Tweet)
Secukinumab Use in Refractory Giant Cell Arteritis
In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/HkMT9QEMg8
Dr. John Cush RheumNow ( View Tweet)
The new (provisional) 2025 EULAR/ACR classification criteria for anti-synthetase syndrome
#EULAR2025 @RheumNow https://t.co/X6VjcN8XZe
Links:
David Liew drdavidliew ( View Tweet)
@RheumNow EULAR haemochromatosis arthropathy classification criteria
Patrick Kiely: please photograph this and take it back to your communities
Patient association lead comes to the microphone, and thanks them for making be seen. 🥲
#EULAR2025 @RheumNow https://t.co/9bqdV0fuPk
David Liew drdavidliew ( View Tweet)
+RCT in #pSjD #Sjogrens #Disease
#Leflunomide + #hydroxychloroquine
Vs #PBO
2nd study to show this - same group
need to know
▶️what pt to use this in
▶️is there diff organ improvements
⬆️#ESSDAI
⬇️RF ⬇️Ig’s
Easy to prescribe
?early, mild dx
#EULAR2025 @RheumNow @eular_org https://t.co/JE0VyFRXc6
Links:
Janet Pope Janetbirdope ( View Tweet)
What ‘CAR’ to drive?
#CAR-T buzz was at #EULAR2025
In multiple #rheumatic #diseases
#SLE
#Scleroderma
#Sjogrens
#myositis
Even #axial #SpA
Who - active, not a lot of damage
Which target 🎯
Which priming regiment
What will results be compared to?
Who will pay?
@RheumNow
Janet Pope Janetbirdope ( View Tweet)
Late-Onset Disease: Different Age, Different Rules?
We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related https://t.co/ubVRhhRGxG
Dr. John Cush RheumNow ( View Tweet)
Biologic switching in PsA:
-Retrospective study on 3,851 PsA pts initiating bDMARDs, 1,848 (48%) switched therapy at least once.
-TNFis were the initial therapy.
-IL17i were the first switch in both single-switch and multi-switch scenarios.
-Subsequent switches: back to TNFi https://t.co/tJDJvPeu9T
Adela Castro AdelaCastro222 ( View Tweet)
#EULAR2025 Abstr#OP0204 Limitations of #SLE Damage Index (SDI): outdated items definition, missing item & unclear use in children. Revised SDI (SLICC-ACR-LFA) via data-driven and expert patient-doctor consensus is underway. Next steps: validation and including weighting @RheumNow https://t.co/K5rPgXBPrj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Highlights @eular_org #EULAR2025
RCTs + in CTD/RA #ILD w #PPF LB0003
Lots of #CAR-T studies in #SARDs
Lots of bDMARDs in
#SLE
#APS
#IgG4
#SjD
Neurostimulation 👇
⬇️inflammation
⬇️pain
#RA
#fibromyalgia
#EULAR2025 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Pearls on EGPA:
1. GC are mainstay for mild
dz
2. Organ threatening/relapsing➡️CYP (RTX alternative)
3. W/o organ threatening➡️ anti-IL-5/IL-5R.
4. IL5i are less effective for ENT
5. Consider sx for nasal polyps.
#EULAR2025 @RheumNow https://t.co/zoJEWxafsN
Links:
Adela Castro AdelaCastro222 ( View Tweet)
EULAR FMF recommendations 2025:
still emphasis on colchicine adherence to maximal dose
+/- bDMARDs if needed for control
+/- csDMARDs for residual chronic MSK involvement
new: consider tapering bDMARD if remission >6mo
See the treatment algorithm below⬇️
#EULAR2025 @RheumNow https://t.co/Hy6DOKzfUL
Links:
David Liew drdavidliew ( View Tweet)
